Anaphylm (dibutepinephrine)

Type I allergic reactions including anaphylaxis

Also known as AQST-109

Manufacturer: Aquestive Therapeutics
Regulatory submission: NDA resubmitted September 2026
Launch: Not announced
Last updated: September 21, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

80 evidence topics · 15 sources

Current treatment options and standard of care41 evidence topics · 9 sources
Place in treatment, anticipated use, and care setting7 evidence topics · 6 sources
Heterogeneity of treatment effect10 evidence topics · 5 sources
Care management intervention strategies11 evidence topics · 3 sources
Other product development or post-marketing obligations required by the FDA3 evidence topics · 4 sources
Ongoing post-approval monitoring1 evidence topic · 1 source
Expected outcomes of therapy7 evidence topics · 3 sources